Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ENSC, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| PF614 | Postoperative Pain, Acute | Phase 3 · NCT06602271 | Recruiting |
| Nafamostat Mesylate | Pharmacokinetics | Phase 1 · NCT04406415 | Completed |
| Oxycodone | Recreational Drug Use | Phase 1 · NCT05567354 | Completed |
Also used in these trials (approved or third-party drugs, not ENSC's own candidates): Naltrexone Hydrochloride, Oxycodone Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ENSC holds $676,704 in cash and short-term investments (as of Jun 30, 2026) and burns about $2.7M/quarter from operations, an estimated runway of 0.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ENSC files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENSC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →